Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.

Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, Leimane V.

Int J Tuberc Lung Dis. 2010 Mar;14(3):275-81.

PMID:
20132617
2.

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD.

J Antimicrob Chemother. 2010 Apr;65(4):775-83. doi: 10.1093/jac/dkq017.

PMID:
20150181
3.

[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].

Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.

Kekkaku. 2003 Oct;78(10):611-7. Japanese.

PMID:
14621568
4.

Peripheral neuropathy associated with treatment for multidrug-resistant tuberculosis.

Shin SS, Hyson AM, Castañeda C, Sánchez E, Alcántara F, Mitnick CD, Fawzi MC, Bayona J, Farmer PE, Kim JY, Furin JJ.

Int J Tuberc Lung Dis. 2003 Apr;7(4):347-53.

PMID:
12729340
5.

Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City.

Mannheimer SB, Sepkowitz KA, Stoeckle M, Friedman CR, Hafner A, Riley LW.

Int J Tuberc Lung Dis. 1997 Aug;1(4):319-25.

PMID:
9432387
6.

Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures.

Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rüsch-Gerdes S, Karimovich HA, Kebede Y, Mills C.

PLoS One. 2007 Nov 7;2(11):e1126.

7.

Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.

Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, Skripconoka V, Wells CD, Leimane V.

Ann Intern Med. 2006 May 2;144(9):650-9.

PMID:
16670134
8.

Linezolid in the treatment of MDR-TB: a retrospective clinical study.

Xu HB, Jiang RH, Li L, Xiao HP.

Int J Tuberc Lung Dis. 2012;16(3):358-63. doi: 10.5588/ijtld.11.0493.

PMID:
22640450
9.

Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.

Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, Barnashov A, Karpeichik Y, Andreev YG, Golubchikova VT, Tonkel TP, Yanova GV, Yedilbayev A, Rich ML, Mukherjee JS, Furin JJ, Atwood S, Farmer PE, Keshavjee S.

Int J Tuberc Lung Dis. 2007 Dec;11(12):1314-20.

PMID:
18034952
10.

Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran.

Baghaei P, Tabarsi P, Dorriz D, Marjani M, Shamaei M, Pooramiri MV, Mansouri D, Farnia P, Masjedi M, Velayati A.

Am J Ther. 2011 Mar-Apr;18(2):e29-34. doi: 10.1097/MJT.0b013e3181c0806d.

PMID:
20019591
11.

Treatment of multidrug-resistant tuberculosis in Thailand.

Maranetra KN.

Chemotherapy. 1996;42 Suppl 3:10-5; discussion 30-3. Review.

PMID:
8980862
12.

Treatment of multidrug-resistant tuberculosis.

Cohn DL.

J Hosp Infect. 1995 Jun;30 Suppl:322-8.

PMID:
7560968
13.

Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients.

Podewils LJ, Holtz T, Riekstina V, Skripconoka V, Zarovska E, Kirvelaite G, Kreigere E, Leimane V.

Epidemiol Infect. 2011 Jan;139(1):113-20. doi: 10.1017/S0950268810000907.

PMID:
20429966
14.

Risk factors for multidrug-resistant tuberculosis in Hong Kong.

Law WS, Yew WW, Chiu Leung C, Kam KM, Tam CM, Chan CK, Leung CC.

Int J Tuberc Lung Dis. 2008 Sep;12(9):1065-70.

PMID:
18713506
15.

Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation.

Miller AC, Gelmanova IY, Keshavjee S, Atwood S, Yanova G, Mishustin S, Furin JJ, Shin SS.

Int J Tuberc Lung Dis. 2012 Jul;16(7):891-6. doi: 10.5588/ijtld.11.0795.

PMID:
22507895
16.

Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.

Park SK, Lee WC, Lee DH, Mitnick CD, Han L, Seung KJ.

Int J Tuberc Lung Dis. 2004 Mar;8(3):361-8.

PMID:
15139476
17.

Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006.

Masjedi MR, Tabarsi P, Chitsaz E, Baghaei P, Mirsaeidi M, Amiri MV, Farnia P, Javanmard P, Mansouri D, Velayati AA.

Int J Tuberc Lung Dis. 2008 Jul;12(7):750-5.

PMID:
18544199
18.

Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic.

Kim HJ, Hong YP, Kim SJ, Lew WJ, Lee EG.

Int J Tuberc Lung Dis. 2001 Dec;5(12):1129-36.

PMID:
11769771
19.

Representative drug susceptibility patterns for guiding design of re-treatment regimens for multidrug-resistant tuberculosis in Iran.

Tabarsi P, Nooraki A, Mirsaeidi M, Amiri M, Baghaei P, Farnia P, Kazempour M, Heidarnazhad H, Alipanah N, Mansouri D, Masjedi MR.

Respirology. 2008 Jan;13(1):108-11. doi: 10.1111/j.1440-1843.2007.01201.x.

PMID:
18197919
20.

Prevalence of acquired MDR-TB and HIV co-infection.

Deivanayagam CN, Rajasekaran S, Venkatesan R, Mahilmaran A, Ahmed PR, Annadurai S, Kumar S, Chandrasekar C, Ravichandran N, Pencillaiah R.

Indian J Chest Dis Allied Sci. 2002 Oct-Dec;44(4):237-42.

PMID:
12437236

Supplemental Content

Support Center